The use of drug inhibitors (sunitinib, dasatinib, cabozantinib, vemurafenib, selumetinib, dabrafenib, sorafenib, RDEA-119, CI-1040, vandetanib, encorafenib, regorafenib, pralsetinib, and selpercatinib) targeting RET, BRAF, NRAS, KRAS, and EPHA7 mutations has shown efficacy in reducing tumor progression in thyroid cancer patients. This evidence concerns the gene BRAF and thyroid gland carcinoma.